James Robert Cook
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Robert Cook has a total of 567 co-authors. Here are the top co-authors by number of shared publications:
Ahmet Dogan
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , US
8 shared publications- Elaine S. Jaffe
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
8 shared publications German Ott
Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
8 shared publications- John R. Goodlad
Department of Pathology, NHS Greater Glasgow and Clyde , Glasgow , UK
8 shared publications - Leticia Quintanilla-Martinez
Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany
8 shared publications - Wenbin Xiao
Memorial Sloan Kettering Cancer Center
7 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by Elsevier in Human Pathology
- Vol. 172, 106105
RNA NGS testing provides additional diagnostic and prognostic information over metaphase karyotyping in routine clinical evaluation of acute leukemias and chronic myeloid neoplasms
- 16 March 2026
- Published by Elsevier in Human Pathology
- Vol. 172, 106105
Open AccessRNA NGS testing provides additional diagnostic and prognostic information over metaphase karyotyping in routine clinical evaluation of acute leukemias and chronic myeloid neoplasms
- 12 December 2025
- Published by Elsevier in Human Pathology
- Vol. 169, 106012
Three practice updates in non-Hodgkin lymphoma for 2026
- 12 December 2025
- Published by Elsevier in Human Pathology
- Vol. 169, 106012
Three practice updates in non-Hodgkin lymphoma for 2026
- Open Access
- 29 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (21) , 5409-5422
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell–like (GCB), and 25% were activated B-cell–like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig− GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.
- 29 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (21) , 5409-5422
Open AccessHigh-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell–like (GCB), and 25% were activated B-cell–like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig− GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.
- Open Access
- 13 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 287-307
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop
The challenging boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 3 focussed on the atypical lymphoid proliferations associated with therapeutic interventions. Forty-four cases were submitted representing a broad spectrum of lymphoproliferative disorders (LPDs) encountered in the settings of immunosuppressive and immunomodulatory therapies, various interventions for solid tumor treatment, drug reaction with eosinophilia and systemic symptoms (DRESS), CAR T-cell therapy for B-cell lymphomas, Bruton tyrosine kinase inhibitors (BTKI) for SLL/CLL treatment, ABL-kinase inhibitor dasatinib, and COVID-19 vaccination. The cases of this session highlighted the importance of having sufficient clinical information including drug history and distribution of disease in order to achieve reliable diagnosis. Among LPDs associated with immunosuppressive and immunomodulatory therapies, the most challenging were T- and NK-derived infiltrates as they ranged from non-clonal to clonal. DRESS-associated lymphadenopathy exhibited variable histologic patterns with the most difficult differential diagnosis being with a T-cell lymphoma. LPDs observed after CAR T-cell therapy for B-cell neoplasms exhibited unexpected phenotypes resulting either from lineage switching/transdifferentiation, or from harvested T-cells already harbouring cancer-associated variants. Temporary interruption of BTKI treatment for CLL/SLL due to surgical procedures led to a “Pseudo-Richter transformation” that disappeared after reintroduction of therapy. Dasatinib led to a lymphadenopathy with a peculiar florid follicular hyperplasia that regressed after discontinuation of therapy. The findings of the few thoroughly studied COVID-19 vaccination associated lymphadenopathy cases reflected a disordered immune response. This report describes the most important features for diagnosis of these challenging cases.
- 13 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 287-307
Open AccessAtypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop
The challenging boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 3 focussed on the atypical lymphoid proliferations associated with therapeutic interventions. Forty-four cases were submitted representing a broad spectrum of lymphoproliferative disorders (LPDs) encountered in the settings of immunosuppressive and immunomodulatory therapies, various interventions for solid tumor treatment, drug reaction with eosinophilia and systemic symptoms (DRESS), CAR T-cell therapy for B-cell lymphomas, Bruton tyrosine kinase inhibitors (BTKI) for SLL/CLL treatment, ABL-kinase inhibitor dasatinib, and COVID-19 vaccination. The cases of this session highlighted the importance of having sufficient clinical information including drug history and distribution of disease in order to achieve reliable diagnosis. Among LPDs associated with immunosuppressive and immunomodulatory therapies, the most challenging were T- and NK-derived infiltrates as they ranged from non-clonal to clonal. DRESS-associated lymphadenopathy exhibited variable histologic patterns with the most difficult differential diagnosis being with a T-cell lymphoma. LPDs observed after CAR T-cell therapy for B-cell neoplasms exhibited unexpected phenotypes resulting either from lineage switching/transdifferentiation, or from harvested T-cells already harbouring cancer-associated variants. Temporary interruption of BTKI treatment for CLL/SLL due to surgical procedures led to a “Pseudo-Richter transformation” that disappeared after reintroduction of therapy. Dasatinib led to a lymphadenopathy with a peculiar florid follicular hyperplasia that regressed after discontinuation of therapy. The findings of the few thoroughly studied COVID-19 vaccination associated lymphadenopathy cases reflected a disordered immune response. This report describes the most important features for diagnosis of these challenging cases.
- Open Access
- 1 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 275-286
Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop
Session 2 of the 2024 European Association for Haematopathology/Society for Hematopathology lymphoma workshop was dedicated to atypical lymphoproliferations in association with germline genetic variants. The first group of cases were lymphoproliferations occurring in the context of primary immunodeficiencies (PID), a heterogeneous group of diseases with increasing incidence and number of different diseases due to better recognition. The workshop contained a spectrum of different PIDs and associated lymphoproliferations with autoimmune lymphoproliferative syndrome, activated phosphoinositide 3-kinase delta syndrome, ataxia-telangiectasia and common variable immune deficiency being the most common. Both children and adults were affected, and the diagnosis of an underlying PID often required a high index of suspicion and correlation with clinical presentation and immunological/ infectious workup. Recognition of a PID allows specific treatment and can influence the interpretation of lymphoproliferations occurring in this context. The spectrum of lymphoproliferations ranged from reactive to overt lymphoma, both EBV-positive and -negative. In a subset of cases, it was very difficult or impossible to establish the boundary between reactive and neoplastic in the context of a PID. The second group represented a heterogeneous group of lymphoproliferations in the context of mutations in germline haematopoietic malignancy risk genes, without associated immunodeficiency. It was often difficult to determine if the genetic defect and the lymphoproliferation were causally related or coincidental, especially if the patient was also treated for non-lymphoid conditions. This is a rapidly evolving field in which future studies are expected to shed more light on the relationship between germline mutations and lymphoid malignancy.
- 1 August 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 275-286
Open AccessAtypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop
Session 2 of the 2024 European Association for Haematopathology/Society for Hematopathology lymphoma workshop was dedicated to atypical lymphoproliferations in association with germline genetic variants. The first group of cases were lymphoproliferations occurring in the context of primary immunodeficiencies (PID), a heterogeneous group of diseases with increasing incidence and number of different diseases due to better recognition. The workshop contained a spectrum of different PIDs and associated lymphoproliferations with autoimmune lymphoproliferative syndrome, activated phosphoinositide 3-kinase delta syndrome, ataxia-telangiectasia and common variable immune deficiency being the most common. Both children and adults were affected, and the diagnosis of an underlying PID often required a high index of suspicion and correlation with clinical presentation and immunological/ infectious workup. Recognition of a PID allows specific treatment and can influence the interpretation of lymphoproliferations occurring in this context. The spectrum of lymphoproliferations ranged from reactive to overt lymphoma, both EBV-positive and -negative. In a subset of cases, it was very difficult or impossible to establish the boundary between reactive and neoplastic in the context of a PID. The second group represented a heterogeneous group of lymphoproliferations in the context of mutations in germline haematopoietic malignancy risk genes, without associated immunodeficiency. It was often difficult to determine if the genetic defect and the lymphoproliferation were causally related or coincidental, especially if the patient was also treated for non-lymphoid conditions. This is a rapidly evolving field in which future studies are expected to shed more light on the relationship between germline mutations and lymphoid malignancy.
- 23 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 309-325
Indolent pediatric lymphomas/lymphoproliferative disorders: a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between indolent neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 4 focused on the revision of indolent pediatric lymphoid neoplasms/lymphoproliferations. Forty-one cases were submitted, representing good examples of indolent pediatric lymphomas/lymphoproliferations and their diagnostic challenges. The morphologic spectrum of pediatric-type follicular lymphoma (PTFL) was discussed, especially exploring unifying features of cases with and without marginal zone differentiation (MZD) (the first also referred to as pediatric nodal marginal zone lymphoma). Unusual features like relapses/recurrences; extranodal involvement and high proliferation rate in the marginal zone differentiated component were observed in PTFL with or without MZD. Rare follicle center-derived neoplasms occurring in children other than PTFL where discussed, such as primary testicular follicular lymphoma and follicle center lymphoma of the lower female genital tract. Testicular follicular lymphomas were compared to cases known from literature, defining a better picture of their clinicopathological features. The criteria for the diagnosis of atypical lymphoid hyperplasia were reviewed and nodal and extranodal cases are discussed. Plasmacytic proliferations in the pediatric population are exceedingly rare, but do exist in clonal and non-clonal forms. A heterogeneous group of extranodal lymphomas is included, among them extranodal marginal zone lymphomas (MZL) of the stomach with a large cell transformation and an intramuscular MZL with comparable features of a cutaneous MZL/lymphoproliferation with IgG4 expression. In this report, the different spectrum of indolent pediatric lymphomas compared to the adult counterpart will be highlighted, to avoid misdiagnosis and overtreatment.
- 23 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 309-325
Indolent pediatric lymphomas/lymphoproliferative disorders: a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between indolent neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 4 focused on the revision of indolent pediatric lymphoid neoplasms/lymphoproliferations. Forty-one cases were submitted, representing good examples of indolent pediatric lymphomas/lymphoproliferations and their diagnostic challenges. The morphologic spectrum of pediatric-type follicular lymphoma (PTFL) was discussed, especially exploring unifying features of cases with and without marginal zone differentiation (MZD) (the first also referred to as pediatric nodal marginal zone lymphoma). Unusual features like relapses/recurrences; extranodal involvement and high proliferation rate in the marginal zone differentiated component were observed in PTFL with or without MZD. Rare follicle center-derived neoplasms occurring in children other than PTFL where discussed, such as primary testicular follicular lymphoma and follicle center lymphoma of the lower female genital tract. Testicular follicular lymphomas were compared to cases known from literature, defining a better picture of their clinicopathological features. The criteria for the diagnosis of atypical lymphoid hyperplasia were reviewed and nodal and extranodal cases are discussed. Plasmacytic proliferations in the pediatric population are exceedingly rare, but do exist in clonal and non-clonal forms. A heterogeneous group of extranodal lymphomas is included, among them extranodal marginal zone lymphomas (MZL) of the stomach with a large cell transformation and an intramuscular MZL with comparable features of a cutaneous MZL/lymphoproliferation with IgG4 expression. In this report, the different spectrum of indolent pediatric lymphomas compared to the adult counterpart will be highlighted, to avoid misdiagnosis and overtreatment.
- Open Access
- 12 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 253-273
The morphological spectrum of Castleman disease and related disorders: a report from the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology
Castleman disease (CD) is an intriguing and complicated group of local and systemic disorders mainly affecting lymph nodes with heterogeneous presentation and therapeutic needs. These disorders were the topic of Session 1 of the Lymphoma Workshop at the 2024 EA4HP in Dubrovnik, Croatia. In this report, we summarize the features of the 85 submitted cases and review the differential diagnosis, pitfalls, and advances for all CD subtypes. Specifically, the molecular landscape of unicentric CD and its relationship with follicular dendritic cell proliferations and indolent T-lymphoblastic proliferation will be discussed. The spectrum of idiopathic multicentric CD (MCD), TAFRO syndrome, as well as the clinical and histopathological peculiarities of POEMS-CD, is reviewed. Cases of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8) + MCD were the most complicated and well demonstrated the difficulties and overlaps in the differential diagnosis of KSHV/HHV8 + lymphoproliferative disorders. Finally, the important topic of CD mimickers will be addressed, demonstrating how the integration of clinical, laboratory, histopathological, and molecular data is mandatory to confirm a diagnosis of CD and how to distinguish it from the many neoplastic, autoimmune, and infective mimickers.
- 12 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 253-273
Open AccessThe morphological spectrum of Castleman disease and related disorders: a report from the Lymphoma Workshop of the 22nd Meeting of the European Association of Hematopathology
Castleman disease (CD) is an intriguing and complicated group of local and systemic disorders mainly affecting lymph nodes with heterogeneous presentation and therapeutic needs. These disorders were the topic of Session 1 of the Lymphoma Workshop at the 2024 EA4HP in Dubrovnik, Croatia. In this report, we summarize the features of the 85 submitted cases and review the differential diagnosis, pitfalls, and advances for all CD subtypes. Specifically, the molecular landscape of unicentric CD and its relationship with follicular dendritic cell proliferations and indolent T-lymphoblastic proliferation will be discussed. The spectrum of idiopathic multicentric CD (MCD), TAFRO syndrome, as well as the clinical and histopathological peculiarities of POEMS-CD, is reviewed. Cases of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8) + MCD were the most complicated and well demonstrated the difficulties and overlaps in the differential diagnosis of KSHV/HHV8 + lymphoproliferative disorders. Finally, the important topic of CD mimickers will be addressed, demonstrating how the integration of clinical, laboratory, histopathological, and molecular data is mandatory to confirm a diagnosis of CD and how to distinguish it from the many neoplastic, autoimmune, and infective mimickers.
- Open Access
- 5 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 327-347
Exploring the boundaries between neoplastic and reactive lymphoproliferations: lymphoid neoplasms with indolent behavior and clonal lymphoproliferations—a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 5 focused on indolent lymphoid neoplasms and clonal lymphoproliferations. Seventy-two cases were submitted, representing good examples of indolent lymphomas and lymphoproliferative disorders (LPD) and their diagnostic challenges. The morphologic spectrum of primary cutaneous marginal zone lymphoma/lymphoproliferation (PC-MZL/PC-MZLPD) was discussed. PC-MZL/PC-MZLPD is divided in the immunoglobulin heavy chain switched-type and non-switched-type with some clinicopathological differences. The overlapping features between PC-MZL/PC-MZLPD and PC-CD4 + T-cell LPD were highlighted. The criteria for the diagnosis of indolent T-lymphoblastic proliferation (iT-LBP) were reviewed. Indolent T-cell lymphoproliferation of the gastrointestinal tract (iT-LPD-GI) is a rare clonal, non-destructive, and non-epitheliotropic T-cell LPD occurring in adults with a male predominance. The cases submitted to the workshop revealed clinicopathological heterogeneity. Unusual features like infiltration of the complete intestinal wall, mesenteric lymph node involvement, and splenomegaly were observed. A novel group of PD1 + /CD4 + indolent cases with intestinal tropism and dissemination to blood, bone marrow, lymph node, and skin was identified. Other indolent clonal B- and T-cell LPDs were discussed including transient, clonal CD8 + T-cell proliferations, usually the result of immune-mediated cytotoxic T-cell response to virus or neoantigens, and the recently described follicle center lymphoma (FLC) of the lower female genital tract. The increasing awareness of the existence of indolent LPDs should avoid unnecessary treatments. In this report, novel findings, recommendations for diagnosis, open questions, and diagnostic challenges raised by the cases submitted to the workshop will be discussed.
- 5 July 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (2) , 327-347
Open AccessExploring the boundaries between neoplastic and reactive lymphoproliferations: lymphoid neoplasms with indolent behavior and clonal lymphoproliferations—a report of the 2024 EA4HP/SH lymphoma workshop
The boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 5 focused on indolent lymphoid neoplasms and clonal lymphoproliferations. Seventy-two cases were submitted, representing good examples of indolent lymphomas and lymphoproliferative disorders (LPD) and their diagnostic challenges. The morphologic spectrum of primary cutaneous marginal zone lymphoma/lymphoproliferation (PC-MZL/PC-MZLPD) was discussed. PC-MZL/PC-MZLPD is divided in the immunoglobulin heavy chain switched-type and non-switched-type with some clinicopathological differences. The overlapping features between PC-MZL/PC-MZLPD and PC-CD4 + T-cell LPD were highlighted. The criteria for the diagnosis of indolent T-lymphoblastic proliferation (iT-LBP) were reviewed. Indolent T-cell lymphoproliferation of the gastrointestinal tract (iT-LPD-GI) is a rare clonal, non-destructive, and non-epitheliotropic T-cell LPD occurring in adults with a male predominance. The cases submitted to the workshop revealed clinicopathological heterogeneity. Unusual features like infiltration of the complete intestinal wall, mesenteric lymph node involvement, and splenomegaly were observed. A novel group of PD1 + /CD4 + indolent cases with intestinal tropism and dissemination to blood, bone marrow, lymph node, and skin was identified. Other indolent clonal B- and T-cell LPDs were discussed including transient, clonal CD8 + T-cell proliferations, usually the result of immune-mediated cytotoxic T-cell response to virus or neoantigens, and the recently described follicle center lymphoma (FLC) of the lower female genital tract. The increasing awareness of the existence of indolent LPDs should avoid unnecessary treatments. In this report, novel findings, recommendations for diagnosis, open questions, and diagnostic challenges raised by the cases submitted to the workshop will be discussed.
- 30 June 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (3) , 278-282
IRTA1 expression in extranodal marginal zone (MALT) lymphoma is variable across anatomic sites
Objective: Immune receptor translocation-associated 1 (IRTA1) expression, which has recently been shown to be highly specific for marginal zone lymphoma, is found in only a subset of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In this study, we examined whether IRTA1 expression in MALT lymphoma was dependent on anatomic location. Methods: IRTA1 immunohistochemistry was performed in 60 cases of extranodal MALT lymphoma, arising at breast, conjunctiva, lung, salivary gland, skin, and stomach (10 cases each). Expression was also scored with respect to detailed morphologic features. Results: IRTA1 staining was identified in 25 (42%) cases, ranging from 9 (90%) of 10 in lung to 2 (20%) of 10 in gastric MALT lymphoma. IRTA1 staining was not characteristic of specific morphologic features, as it was absent in most lymphoepithelial lesions, perifollicular cells, cells with overt monocytoid cytology, and plasmacytic cells. IRTA1 expression was also identified in 5 (50%) of 10 cases of pulmonary nodular lymphoid hyperplasia. Conclusions: IRTA1 expression is heterogeneous in extranodal MALT lymphoma. Staining for IRTA1 is not characteristic of specific morphologic features, but varies with the anatomic site of disease. Knowledge of site-specific differences in MALT lymphomas will facilitate diagnosis in routine clinical practice.
- 30 June 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (3) , 278-282
IRTA1 expression in extranodal marginal zone (MALT) lymphoma is variable across anatomic sites
Objective: Immune receptor translocation-associated 1 (IRTA1) expression, which has recently been shown to be highly specific for marginal zone lymphoma, is found in only a subset of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In this study, we examined whether IRTA1 expression in MALT lymphoma was dependent on anatomic location. Methods: IRTA1 immunohistochemistry was performed in 60 cases of extranodal MALT lymphoma, arising at breast, conjunctiva, lung, salivary gland, skin, and stomach (10 cases each). Expression was also scored with respect to detailed morphologic features. Results: IRTA1 staining was identified in 25 (42%) cases, ranging from 9 (90%) of 10 in lung to 2 (20%) of 10 in gastric MALT lymphoma. IRTA1 staining was not characteristic of specific morphologic features, as it was absent in most lymphoepithelial lesions, perifollicular cells, cells with overt monocytoid cytology, and plasmacytic cells. IRTA1 expression was also identified in 5 (50%) of 10 cases of pulmonary nodular lymphoid hyperplasia. Conclusions: IRTA1 expression is heterogeneous in extranodal MALT lymphoma. Staining for IRTA1 is not characteristic of specific morphologic features, but varies with the anatomic site of disease. Knowledge of site-specific differences in MALT lymphomas will facilitate diagnosis in routine clinical practice.
- 1 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (5) , 525-540
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.
- 1 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (5) , 525-540
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.